Proton radiation and intrathecal chemo for lung cancer that has spread to the brain lining
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of proton radiation to the brain and spine plus chemotherapy given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and has continued to grow despite taking a third-generation TKI medicine like osimertinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer with an EGFR mutation (like 19del or L858R).
- The cancer has spread to the lining of the brain (called leptomeningeal metastasis).
- You were treated with a third-generation TKI (like osimertinib, almonertinib, or furmonertinib) and the brain lining disease got worse, but the cancer outside the brain is stable.
- You have a small device under the scalp (called an Ommaya reservoir) for giving medicine into the spinal fluid, or you are willing to have one placed.
- You are generally well enough to handle the treatment, with a Karnofsky score of 70 or above and a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
Hear when a new Leptomeningeal Metastasis From Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.